GLAXOSMITHKLINE PLC Form 6-K October 18, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company') Transaction notification							
	Details of PDMR/person closely associa	ted with then	n ('PCA')				
	Name	Dr M M Sla					
	Position/status		Global Vaccines				
c)	Initial notification/ amendment	Initial notifi					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a) b)	Name LEI	GlaxoSmith 5493000HZ	Kline plc TVUYLO1D793				
-)	Details of the transaction(s): section to b						
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted						
a)	Description of the financial instrument	American Depositary Shares ('ADSs')					
		ISIN: US37733W1053					
b)	Nature of the transaction	in ADSs foll re-investmen paid to share October 201 in the Comp	ease in notional interest DSs following the nyestment of dividends to shareholders on 13 ober 2016 on ADSs held the Company's 2009 formance Share Plan.				
c)	Price(s) and	Price(s)	Volume(s)				
0)	volume(s)						
		\$42.39	1414.687				
		\$42.39	1569.750				
		\$42.39	1797.585				
	Aggregated information						
d)	Aggregated volume Price	4,782.022 \$42.39					
e)	Date of the transaction	2016-10-13					
	Place of the transaction	n/a					
1.	Details of PDMR/person closely associa	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Mr N Hirons					
h)	Position/status	SVP, Global Ethics &					
0)		Compliance					
c)	Initial notification/ amendment	Initial notification					
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor						
a)	Name	GlaxoSmithKline plc					

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

 b) LEI 5493000HZTVUYLO1D7 Details of the transaction(s): section to be repeated for (i) each type 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted American Depositary Share a) Description of the financial instrument ('ADSs') ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs he in the Company's 2009 Performance Share Plan. c) Price(s) and volume(s) c) Price(s) and volume(s) d) Aggregated information d) Aggregated volume price e) Date of the transaction 	of h res st					
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted American Depositary Share ('ADSs') ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs he in the Company's 2009 Performance Share Plan. c) Price(s) and volume(s) Aggregated information Aggregated volume Price Date of the transaction 2016-10-13 	h res st					
 a) Description of the financial instrument a) Description of the financial instrument b) Description of the financial instrument b) Nature of the transaction b) Nature of the transaction c) Price(s) and volume(s) c) Price(s) and volume(s) d) Aggregated information d) Aggregated volume Price e) Date of the transaction 	st S					
 a) Description of the financial instrument ('ADSs') ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs he in the Company's 2009 Performance Share Plan. c) Price(s) and volume(s) Aggregated information d) Aggregated volume Price e) Date of the transaction a) Description of the financial instrument ('ADSs') ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs he in the Company's 2009 Performance Share Plan. b) Price(s) and volume(s) \$42.39 85.247 c) Aggregated volume Price c) Date of the transaction c) 2016-10-13 	st S					
 ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs he in the Company's 2009 Performance Share Plan. Price(s) and volume(s) Aggregated information Aggregated volume Price Date of the transaction ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs he in the Company's 2009 Performance Share Plan. Price(s) Volume(s) \$42.39 85.247 Aggregated volume Price Date of the transaction 2016-10-13 	8					
 b) Nature of the transaction b) Nature of the transaction c) Price(s) and volume(s) Aggregated information d) Aggregated volume Price e) Date of the transaction in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs he in the Company's 2009 Performance Share Plan. Price(s) and Price(s) Volume(s) \$42.39 85.247 Aggregated volume n/a (single transaction) price 	8					
 b) Nature of the transaction b) Nature of the transaction c) Price(s) and volume(s) d) Aggregated information d) Aggregated volume Price e) Date of the transaction 						
 b) Nature of the transaction paid to shareholders on 13 October 2016 on ADSs here in the Company's 2009 Performance Share Plan. c) Price(s) and volume(s) Price(s) Volume(s) \$42.39 85.247 d) Aggregated information d) Aggregated volume Price e) Date of the transaction 2016-10-13 						
 c) Price(s) and volume(s) d) Aggregated volume Price e) Date of the transaction in the Company's 2009 Performance Share Plan. Price(s) Volume(s) \$42.39 85.247 85.247 Na (single transaction) 2016-10-13 	ld					
 c) Price(s) and volume(s) Aggregated information d) Aggregated volume Price e) Date of the transaction Performance Share Plan. Price(s) Volume(s) \$42.39 85.247 85.247 Na (single transaction) 2016-10-13 						
 c) Price(s) and volume(s) Aggregated information Price(s) Volume(s) \$42.39 85.247 Aggregated volume n/a (single transaction) Price e) Date of the transaction 2016-10-13 						
 volume(s) Aggregated information Aggregated volume Price bate of the transaction 2016-10-13 						
Aggregated informationd) Aggregated volume Pricen/a (single transaction)e) Date of the transaction2016-10-13						
 d) Aggregated volume n/a (single transaction) Price e) Date of the transaction 2016-10-13 						
Price e) Date of the transaction 2016-10-13						
e) Date of the transaction 2016-10-13						
f) Place of the transaction n/a						
. Details of PDMR/person closely associated with them ('PCA')						
a) Name Mr B McNamara						
b) Position/status CEO, GSK Consumer Healthcare						
Initial notification/						
amendment	Initial notification					
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	Details of the issuer, emission allowance market participant, auction					
a) Name GlaxoSmithKline plc						
,	5493000HZTVUYLO1D793					
Details of the transaction(s): section to be repeated for (i) each type 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each						
place where transaction(s) has been conducted						
American Depositary Shar	es					
a) Description of the financial instrument ('ADSs') ISIN: US37733W1053	('ADSs') ISIN: US37733W1053					
Increase in notional interes	st					
in ADSs following the	-					
b) Nature of the transaction re-investment of dividends paid to shareholders on 13						
b) Nature of the transaction paid to shareholders on 15						
October 2016 on ADSs he						
October 2016 on ADSs he in the Company's 2009						
October 2016 on ADSs he in the Company's 2009 Performance Share Plan.						
October 2016 on ADSs he in the Company's 2009						

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	- 3	5	-			
		\$42.39	71.440			
		\$42.39	211.994			
		\$42.39				
		\$42.39	551.108			
	Aggregated information	ψ12.37	551.100			
d)	Aggregated volume					
,	Price	1234.048				
		\$42.39				
e)	Date of the transaction	2016-10-13				
	Place of the transaction	n/a				
	Details of PDMR/person closely associa	ated with the	m ('PCA')			
	Name	Mr D E Tro				
b)	Position/status	SVP & General Counsel				
,	Initial notification/	T 1				
c)	amendment	Initial notif	cation			
2	Details of the issuer, emission allowance	e market part	icipant, auction			
2.	platform, auctioneer or auction monitor	_	_			
a)	Name	GlaxoSmith	Kline plc			
b)	LEI	5493000HZ	TVUYLO1D793			
	Details of the transaction(s): section to b	be repeated for	or (i) each type of			
3.	instrument; (ii) each type of transaction; (iii) each date; and (iv) each					
	place where transaction(s) has been conducted					
		American E	Depositary Shares			
a)	Description of the financial instrument	('ADSs')				
		ISIN: US37				
		Increase in	notional interest			
		in ADSs fol	e			
			nt of dividends			
b)	Nature of the transaction	paid to shareholders on 13 October 2016 on ADSs held				
		in the Company's 2009				
		Performanc	e Share Plan.			
c)	Price(s) and	Price(s)	Volume(s)			
	volume(s)					
		\$42.39	876.858			
		\$42.39	972.968			
		\$42.39	1128.822			
	Aggregated information					
d)		2978.648				
u)	Aggregated volume	\$42.39				
	Price	\$42.39				
e)	Date of the transaction	2016-10-13				
f)	Place of the transaction	2010-10-13 n/a				
1)	Thee of the transaction	11/ a				
1.	Details of PDMR/person closely associated with them ('PCA')					
a)	Name	Dr K Slaou				
		PCA of Dr M M Slaoui				
	5	(Chairman, Global Vaccines)				
b)	Position/status					
,	Position/status Initial notification/		Global Vaccines)			

amendment

2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	GlaxoSmithKline plc				
b)	LEI	5493000HZTVUYLO1D793				
	Details of the transaction(s): section to b	e transaction(s): section to be repeated for (i) each type of				
3.	instrument; (ii) each type of transaction;	; (iii) each date; and (iv) each				
	place where transaction(s) has been conducted					
		American D	epositary Shares			
a)	Description of the financial instrument	('ADSs')				
		ISIN: US37733W1053				
		Increase in notional interest				
		in ADSs following the				
		re-investment of dividends				
b)	Nature of the transaction	paid to shareholders on 13				
			6 on ADSs held			
		in the Comp	•			
		Performance	e Share Plan.			
c)	Price(s) and	Price(s)	Volume(s)			
	volume(s)	\$42.20	22.001			
		\$42.39 \$42.39	22.991 24.324			
		\$42.39 \$42.39	24.324 25.675			
		\$42.39	25.075			
	Aggregated information					
d)		72.99				
u)	Aggregated volume	\$42.39				
	Price	¢				
e)	Date of the transaction	2016-10-13				
f)	Place of the transaction	n/a				
<i>,</i>						

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant) Date: October 17, 2016

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc